JP2014097964A5 - - Google Patents

Download PDF

Info

Publication number
JP2014097964A5
JP2014097964A5 JP2012251831A JP2012251831A JP2014097964A5 JP 2014097964 A5 JP2014097964 A5 JP 2014097964A5 JP 2012251831 A JP2012251831 A JP 2012251831A JP 2012251831 A JP2012251831 A JP 2012251831A JP 2014097964 A5 JP2014097964 A5 JP 2014097964A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
deuterium
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012251831A
Other languages
English (en)
Japanese (ja)
Other versions
JP6146990B2 (ja
JP2014097964A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2012251831A priority Critical patent/JP6146990B2/ja
Priority claimed from JP2012251831A external-priority patent/JP6146990B2/ja
Publication of JP2014097964A publication Critical patent/JP2014097964A/ja
Publication of JP2014097964A5 publication Critical patent/JP2014097964A5/ja
Application granted granted Critical
Publication of JP6146990B2 publication Critical patent/JP6146990B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012251831A 2012-11-16 2012-11-16 重水素化されたcftr増強物質 Active JP6146990B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2012251831A JP6146990B2 (ja) 2012-11-16 2012-11-16 重水素化されたcftr増強物質

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012251831A JP6146990B2 (ja) 2012-11-16 2012-11-16 重水素化されたcftr増強物質

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017022718A Division JP2017105824A (ja) 2017-02-10 2017-02-10 重水素化されたcftr増強物質

Publications (3)

Publication Number Publication Date
JP2014097964A JP2014097964A (ja) 2014-05-29
JP2014097964A5 true JP2014097964A5 (cg-RX-API-DMAC7.html) 2016-01-07
JP6146990B2 JP6146990B2 (ja) 2017-06-14

Family

ID=50940312

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012251831A Active JP6146990B2 (ja) 2012-11-16 2012-11-16 重水素化されたcftr増強物質

Country Status (1)

Country Link
JP (1) JP6146990B2 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2635581C (en) 2005-12-28 2017-02-28 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
KR20130056244A (ko) 2010-04-22 2013-05-29 버텍스 파마슈티칼스 인코포레이티드 시클로알킬카르복스아미도-인돌 화합물의 제조 방법
ES2885181T3 (es) 2014-04-15 2021-12-13 Vertex Pharma Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística
JP6746569B2 (ja) 2014-10-07 2020-08-26 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated 嚢胞性線維症膜貫通コンダクタンス制御因子のモジュレーターの共結晶
AU2016288699B2 (en) * 2015-06-30 2020-11-26 Eiger Group International, Inc. Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions
US10206915B2 (en) 2016-04-25 2019-02-19 Druggability Technologies Ip Holdco Limited Complexes of Ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
HUP1600271A2 (hu) 2016-04-25 2017-10-30 Druggability Tech Ip Holdco Ltd Ivacaftor és Lumacaftor sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadható készítményei
US10383865B2 (en) 2016-04-25 2019-08-20 Druggability Technologies Ip Holdco Limited Pharmaceutical combination composition comprising complex formulations of Ivacaftor and Lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them
HUP1600270A2 (hu) 2016-04-25 2017-10-30 Druggability Tech Ip Holdco Ltd Ivacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadott készítményei
US10995103B2 (en) 2016-07-25 2021-05-04 Shenzhen Targetrx, Inc. Substituted boric acid compound, pharmaceutical composition comprising same, and application thereof
JP2017105824A (ja) * 2017-02-10 2017-06-15 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化されたcftr増強物質
KR102720000B1 (ko) * 2017-12-01 2024-10-21 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막관통 조절 인자의 제조 방법
JP6654223B2 (ja) * 2018-08-13 2020-02-26 バーテックス ファーマシューティカルズ (ヨーロッパ) リミテッド 重水素化されたcftr増強物質
CN115304595A (zh) * 2020-01-10 2022-11-08 康圣博施医药有限公司 药物的治疗组合以及其使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9507200A (pt) * 1994-03-25 1997-09-16 Isotechnika Inc Melhora da eficácia de drogas por deuteração
EA007590B1 (ru) * 2002-04-08 2006-12-29 Пфайзер Инк. Производные тропана в качестве модуляторов ccr5
CA2490121C (en) * 2002-06-20 2013-01-08 Ic Vec Limited Modified phospholipids
ME02799B (me) * 2004-06-24 2018-01-20 Vertex Pharma Modulatori ATP-vezujućih kasetnih transportera
SI3235812T1 (sl) * 2011-05-18 2020-02-28 Vertex Pharmaceuticals (Europe) Limited Devterirani derivati ivakaftorja

Similar Documents

Publication Publication Date Title
JP2014097964A5 (cg-RX-API-DMAC7.html)
JP2014515351A5 (cg-RX-API-DMAC7.html)
JP2015528020A5 (cg-RX-API-DMAC7.html)
JP2018534348A5 (cg-RX-API-DMAC7.html)
JP2015145426A5 (cg-RX-API-DMAC7.html)
JP2013537203A5 (cg-RX-API-DMAC7.html)
JP2013032389A5 (cg-RX-API-DMAC7.html)
JP2015512931A5 (cg-RX-API-DMAC7.html)
JP2014500861A5 (cg-RX-API-DMAC7.html)
JP2015512432A5 (cg-RX-API-DMAC7.html)
JP2013542261A5 (cg-RX-API-DMAC7.html)
JP2011037841A5 (cg-RX-API-DMAC7.html)
JP2016500111A5 (cg-RX-API-DMAC7.html)
JP2013509429A5 (cg-RX-API-DMAC7.html)
JP2017537066A5 (cg-RX-API-DMAC7.html)
JP2010001302A5 (cg-RX-API-DMAC7.html)
JP2015505296A5 (cg-RX-API-DMAC7.html)
JP2016529306A5 (cg-RX-API-DMAC7.html)
JP2016540749A5 (cg-RX-API-DMAC7.html)
JP2012519182A5 (cg-RX-API-DMAC7.html)
JP2012532883A5 (cg-RX-API-DMAC7.html)
JP2013538857A5 (cg-RX-API-DMAC7.html)
JP2016534088A5 (cg-RX-API-DMAC7.html)
JP2017505809A5 (cg-RX-API-DMAC7.html)
JP2015516419A5 (cg-RX-API-DMAC7.html)